Canada
# |
Name |
Cash and Short-Term Investments |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 760.59 M
|
Dec. 31, 2023 | USD 3.17 | -1.86% |
|
Canada |
|
2 |
USD 638.08 M
|
Dec. 31, 2023 | USD 39.98 | -1.21% |
|
Canada |
|
3 |
USD 374.33 M
|
Dec. 31, 2023 | USD 14.60 | -0.95% |
|
Canada |
|
4 |
USD 350.49 M
|
Dec. 31, 2023 | USD 7.95 | -0.62% |
|
Canada |
|
5 |
USD 223.63 M
|
Dec. 31, 2023 | USD 1.22 | 2.52% |
|
Canada |
|
6 |
USD 116.51 M
|
Dec. 31, 2023 | USD 4.00 | 3.39% |
|
Canada |
|
7 |
USD 40.85 M
|
Nov. 30, 2023 | USD 1.52 | 2.02% |
|
Canada |
|
8 |
USD 39.83 M
|
Dec. 31, 2023 | USD 9.51 | -0.80% |
|
Canada |
|
9 |
USD 26.21 M
|
Dec. 31, 2023 | USD 6.23 | -0.19% |
|
Canada |
|
10 |
USD 21.95 M
|
Dec. 31, 2023 | USD 2.96 | 1.10% |
|
Canada |
|
11 |
USD 6.61 M
|
June 30, 2024 | USD 3.15 | 0.64% |
|
Canada |
|
12 |
USD 6.56 M
|
Aug. 31, 2024 | USD 1.86 | 5.08% |
|
Canada |
|
13 |
USD 5.36 M
|
Sept. 30, 2023 | USD 1.91 | 1.06% |
|
Canada |
|
14 |
USD 5.25 M
|
March 31, 2024 | USD 2.65 | -1.93% |
|
Canada |
|
15 |
USD 3.45 M
|
Dec. 31, 2023 | USD 0.89 | -2.92% |
|
Canada |
The Clinical Trials company in Canada with the highest Cash and Short-Term Investments is AbCellera Biologics Inc. (NasdaqGS: ABCL) at USD 760.59 M.
The Clinical Trials company in Canada with the lowest Cash and Short-Term Investments is XORTX Therapeutics Inc. (TSXV: XRTX.V) at USD 3.45 M.
The top 10 Clinical Trials companies in Canada by Cash and Short-Term Investments are AbCellera Biologics Inc., Xenon Pharmaceuticals Inc., Zymeworks Inc., Aurinia Pharmaceuticals Inc., Repare Therapeutics Inc., Knight Therapeutics Inc., Theratechnologies Inc., Cipher Pharmaceuticals Inc., Profound Medical Corp. and HLS Therapeutics Inc..
The bottom 10 Clinical Trials companies in Canada by Cash and Short-Term Investments are XORTX Therapeutics Inc., Medexus Pharmaceuticals Inc., Edesa Biotech, Inc., Lexaria Bioscience Corp., InMed Pharmaceuticals Inc., HLS Therapeutics Inc., Profound Medical Corp., Cipher Pharmaceuticals Inc., Theratechnologies Inc. and Knight Therapeutics Inc..